Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by ...

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...

Bristol Myers Squibb shares rose Friday, a day after its schizophrenia drug was approved for use by the Food and Drug Administration.

Analyst Chris Shibutani from Goldman Sachs reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report) and keeping the price ...

Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and increased the price target to $53.00 from $48.00. Evan Seigerman has given ...

After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...

Bristol-Myers Squibb's acquisition of Karuna for $14bn and the subsequent FDA approval of Cobenfy, a novel schizophrenia drug, represents a significant strategic win. Cobenfy, the first new ...

Institutions' substantial holdings in Bristol-Myers Squibb implies that they have significant influence over the company's share price 48% of the business is held by the top 25 shareholders ...